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Abstract 
 
Aims 
Prescribing is a complex skill required of doctors and, increasingly, other healthcare 
professionals. Use of a personal formulary can help to develop this skill. In 2006-9, we 
developed a core list of the 100 most commonly prescribed drugs. Our aim in the present 
study was to update this ‘starter formulary’ to ensure its continued relevance for prescriber 
training. 
Methods 
We analysed large contemporary primary and secondary care datasets to identify the most 
frequently prescribed medicinal products. Items were classified into natural groups, broadly 
following their British National Formulary classification. The resulting drug groups were 
included in the core list if they comprised ≥0.1% prescriptions in both settings or ≥0.2-0.3% 
prescriptions in one setting. Drugs from emergency guidelines that did not qualify by 
prescribing frequency completed the list. 
Results 
Over 1 billion primary care items and approximately 1.8 million secondary care prescriptions 
were analysed. The updated list comprises 81 drug groups commonly prescribed in both 
settings; 6 from primary care; 7 from secondary care; and 6 from emergency guidelines. 88% 
of the formulary was unchanged. Notable changes include entry of newer anti-epileptics 
and dipeptidyl peptidase-4 inhibitors and exit of phenytoin and thiazolidinediones. 
Conclusions 
The relative stability of the core drug list over 9 years and the current update ensure that 
learning based on this list remains relevant to practice. Trainee prescribers may be 
encouraged to use this ‘starter formulary’ to develop a sound basis of prescribing 
knowledge and skills that they can subsequently apply more widely. 
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Structured summary 
1: What is already known about this subject:  
 Prescribing is a complex skill, acquisition of which can be facilitated by use of a 
personal formulary 
 In 2006-9 we developed a ‘starter formulary’ of the 100 drugs most commonly 
prescribed in the UK 
 This drug list remained stable over 2 years and was consistent with practice of new 
prescribers 
2: What this study adds:  
 We used primary and secondary prescribing data from 2015 to update the ‘starter 
formulary’ 
 Most drugs in the list remain the same, with 12 differences attributable to changes 
in practice, disease prevalence and methodology 
 The list is intended not to stifle trainees’ inquisitiveness, but to provide an evidence-
based starting point from which they can build their prescribing knowledge and skills 
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Introduction 
In Outcomes for Graduates, the General Medical Council emphasises the safe, effective and 
economical prescription of drugs as a core skill for all new UK medical graduates [1]. The 
importance of prescribing skills is further emphasised by the UK Prescribing Safety 
Assessment, which all new doctors must pass as a requirement of the Foundation 
Programme [2,3]. Prescribing is a complex, multi-step process that includes defining the 
clinical problem and therapeutic objectives; identifying a suitable treatment; starting the 
treatment; giving appropriate information; and monitoring treatment success [4]. The 
challenge faced by trainee prescribers in acquiring this skill is compounded by the large 
number of drugs available. For example, in the UK, 1,603 drugs and 18,408 preparations are 
licensed for prescription [personal communication, British National Formulary (BNF) 
editorial team, October 2017]. 
To facilitate development and maintenance of prescribing competence, the World Health 
Organisation (WHO) recommends that prescribers develop a list of ‘P’ drugs – a personal 
formulary of drugs that they prescribe regularly and can become familiar with [4]. This is 
difficult for undergraduate medical students who are not yet prescribing and who may see 
diverse practice as they rotate through healthcare settings and specialties. De Vries and 
colleagues found that provision of any formulary, whether learner or teacher-led, helped 
students to improve their prescribing skills [5]. In 2011, we therefore developed a ‘starter 
formulary’ of the 100 drugs most commonly prescribed in the UK from analysis of primary 
and secondary care prescribing data [6]. This helped students to focus their initial learning 
on drugs they would actually prescribe in practice and supported educators in developing 
learning resources and assessments [7]. 
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Our original list was developed from analysis of primary and secondary care prescribing data 
from 2006-9. Over the last 5-10 years, there have been significant therapeutic advances, 
including the advent of direct oral anticoagulants and dipeptidyl peptidase 4 inhibitors. The 
aim of this study was to update the starter formulary by identifying the drugs most 
commonly prescribed in primary and secondary care in 2015, thereby supporting relevant 
modern-day learning for new prescribers. 
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Methods 
Overview 
NHS Prescription Cost Analysis (PCA) data was used to identify all items dispensed in the 
community in England in 2015 [8]. Electronic prescription records were used to identify all 
items prescribed in the University Hospital Birmingham NHS Foundation Trust in 2015. 
Medicinal products identified in each healthcare setting were formed into natural groups, 
guided by their classification in the British National Formulary (BNF) [9]. The most 
commonly prescribed drug groups in both or either setting were combined with drugs 
identified from emergency guidelines to generate the final core drug list. 
Study approvals 
This study did not require ethical approval as it was based wholly on aggregate data, with no 
linkage to patient-level data  
Data collection 
Primary care 
NHS PCA data for England 2015 was obtained. This is based on information obtained from 
prescriptions sent to the Prescription Pricing Division of the NHS Business Services 
Authority. All prescriptions dispensed in the community are included, the majority of which 
are written by general practitioners. Analysis was based on the frequency with which each 
medicinal product was dispensed. 
Secondary care 
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A list of all items prescribed in University Hospital Birmingham NHS Foundation Trust in 
2015 was obtained from their electronic prescribing system. Analysis was based on the 
frequency of medicinal product prescription. 
Emergency drugs  
A review of hospital guidelines generated a list of all emergency drugs used in hospital 
emergency settings [10]. 
Compiling the core list 
In accordance with a prospectively defined analysis plan, the PCA dataset was cleaned to 
remove items that fell outside the definition of a medicinal product [11] (e.g. sunscreens, 
camouflages, appliances and nutritional supplements). We also removed intravenous fluid 
preparations and vaccines because, although they fall within the definition of medicinal 
products, we judged that they represent educationally distinct groups. Finally, we planned 
to apply clinical–educational judgment to remove drugs used in highly specialised practice 
that fell outside the scope of a core drug list for trainee prescribers. 
The PCA data was used to develop natural drug groups. Medicinal products were first 
classified by BNF sub-paragraph. The products within each sub-paragraph were then 
classified by chemical name to identify and separate individual drug classes. Where several 
chemical entities fell naturally into a drug class, this was used as a group for analysis 
purposes. Conversely, where a chemical entity fell into a class of its own, it was named and 
analysed as such. For example, the BNF sub-paragraph ‘Lipid-regulating drugs’ was 
separated into statins, fibrates and ezetimibe. In a few cases, e.g. ‘Nicotine replacement and 
related drugs’, the BNF sub-paragraph was retained as the basis for the drug group. Where 
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necessary, clinical judgment was applied to ensure groupings were natural and clinically 
applicable. The drug groups developed from the PCA data were then used to sort drugs in 
the secondary care data. 
Compound products were not included as distinct items if their constituent ingredients were 
already captured in the top 100 list. Where different members of drug classes were used for 
more than one indication the drug class was included only once (e.g. H1 receptor 
antagonists for nausea, allergy) and the frequencies summed.  
Prescribing frequency 
For the PCA data, the number of items dispensed for all medicinal products within each drug 
group was summed and expressed as a percentage of the total number of items dispensed. 
For the secondary care data, the number of prescriptions written for all medicinal products 
within each drug group was summed and expressed as a percentage of the total number of 
prescriptions. 
Generating the top 100 drug list 
Prior to the analysis it was decided that the list would contain 100 drug groups as a number 
that was educationally attractive, sufficient to cover most prescribing by foundation doctors 
[6] and limited enough to be considered core. 
Drug groups qualified for the top 100 list if they comprised ≥0.1% prescriptions in both 
primary and secondary care; ≥0.2% prescriptions in primary care but <0.1% prescriptions in 
secondary care; or ≥0.3% prescriptions in secondary care but <0.1% prescriptions in primary 
care. These definitions were chosen to optimise inclusion of drugs that were widely 
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prescribed across healthcare systems and to reduce the inclusion of more specialist drugs 
e.g. those with high use by a single specialist team in secondary care but not commonly 
prescribed by non-specialist doctors. As the number of drug groups meeting these criteria 
exceeded 100, clinical and educational judgement was used to review the less commonly 
prescribed drugs from these lists, selecting those considered to be prescribed by generalists 
over those requiring more specialist expertise. In addition drugs from emergency guidelines 
that did not qualify by prescribing frequency but were considered to be clinically important 
were identified and room was made for them on the list by removing more specialist drugs. 
Comparison of methodology between 2006-9 and 2015 
Prescription cost analysis data was used to analyse items dispensed in the community in 
both 2006-9 and 2015 using broadly similar approaches. Minor changes in 2015 included a 
pre-planned decision to exclude intravenous fluids and vaccines from the analysis and to 
exclude combination products (e.g. analgesia, inhalers) from the final list where the 
constituent drugs were already included. 
The main difference between studies was in the methods used to obtain the secondary care 
data. In 2006-9, a by-hand audit of paper drug charts of inpatients in two London hospitals 
was used to identify 7705 individual prescriptions. In 2015, a list of all (2.129 million) items 
prescribed that year in a single large teaching hospital was obtained from their electronic 
prescribing system. The 2015 secondary care data gives a much more comprehensive 
picture of secondary care prescribing, albeit from a single hospital with some distinct 
tertiary practice. 
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Results 
The PCA 2015 dataset comprised 1.037 billion dispensed items, of which 24.775 million 
items were ineligible for inclusion (figure 1). The Birmingham hospital data set comprised 
2.129 million prescriptions, of which 360,000 prescriptions were ineligible for inclusion. The 
primary and secondary care analysis datasets therefore comprised 1.013 billion items 
dispensed and 1.779 million prescriptions respectively. 
Core drug list 
Eighty one drug groups that made up ≥0.1% items dispensed in primary care and 
prescriptions in secondary care comprised the majority of the list (table 1). Two drugs that 
met these criteria (nicorandil, 0.1% hospital prescriptions, 0.3% primary care items; 
hydroxychloroquine 0.1% hospital prescriptions, 0.1% primary care items) were considered 
more for specialist than generalist use and therefore not included in the final list. 
All 5 drug groups that made up ≥0.2% items dispensed in primary care alone were included 
in the core drug list (table 2). In addition, ‘drugs for breast cancer’, comprising 0.19% items 
dispensed) was included. 
Eleven drug groups made up ≥0.3% prescriptions in secondary care alone and 7 of these 
were included in the final list (table 3). The 4 drug groups excluded from the the core final 
list because they were considered to require more specialist than generalist expertise were 
N-Methyl-D-aspartate receptor antagonists (e.g. ketamine), 1.9% prescriptions; 
immunosuppressants (e.g. tacrolimus, ciclosporin), 1.3% prescriptions; drugs for human 
immunodeficiency virus (HIV) infection (e.g. ritonavir), 1.1% prescriptions; and carbapenems 
(e.g. meropenem), 0.5% prescriptions. 
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Six drugs from emergency guidelines that did not qualify by prescribing frequency were 
considered clinically important and completed the list (table 4). 
Changes in core drug list from 2006-2009 to 2015 
There were 12 changes to the core list in 2015 from 2006-9 (table 5). Some of the drugs 
dropping out of the core drug list did so due to changes in qualification rules set in the 
prospectively defined analysis plan. Compound products were not included as distinct items 
if their constituent ingredients were already captured in the top 100 list (compound beta 2 
agonist/corticosteroid inhalers; opioids, compound preparations). Where different 
members of drug classes were used for more than one indication the drug class was 
included only once (anti-histamine anti-emetics and H1 receptor antagonists were separate 
in the old list and combined in the new list). Vaccines and antisera were excluded because, 
although they fall within the definition of medicinal products, we judged that they were 
educationally distinct. Electrolytes were split and analysed as their constituents (e.g. oral 
potassium, oral magnesium, intravenous electrolytes), which didn’t individually make the 
list based on prescribing frequency. 
 
Other drugs dropping out of the core list did so due to a fall in prescribing frequency relative 
to new entrants. These were anti-emetics, phenothiazines; dipyridamole; diuretics, 
potassium-sparing diuretics with other diuretics; laxatives, bulk forming, phenytoin and 
thiazolidinediones. Nicorandil was borderline for inclusion on the basis of prescribing 
frequency, but was excluded from the final list to make room for emergency medicines as it 
was judged more specialist than generalist compared to other borderline drugs. 
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All new entrants to the list qualified through an increase in relative prescribing frequency. 
For some drugs this represents a genuine increase in use e.g. direct oral anticoagulants, 
DPP-4 inhibitors, levetiracetam. For others, drug use may have remained constant but 
increased relative to some of those leaving the list (e.g. thiazolidinediones, phenytoin) 
where use has decreased. 
Comparison of core drugs list to the World Health Organisation list of essential medicines 
The World Health Organisation (WHO) compiles and updates a core list of minimum 
medicines required for a basic health-care system and a complementary list of essential 
medicines for priority diseases where some specialist facilities, care or training are needed 
for their use [12]. Together these lists contain around 438 individual drugs. To determine 
the applicability of the core drug list to trainee prescribers working in healthcare systems 
outside England we compared our list to the World Health Organisation list of essential 
medicines [12]. Seventy eight percent of our core drugs were on the WHO essential list and 
4% were on the complementary list. Drugs not on the WHO list or on the complementary list 
only are shown in table 6. 
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Discussion 
We have identified the drug groups most commonly prescribed in England in primary and 
secondary care settings in 2015. We have used this analysis to develop a ‘top 100 drugs’ list 
to provide a starting point for trainee prescribers being introduced to pharmacology for the 
first time. This new list updates our previous analysis of 2006-9 prescribing data [6]. 
Reassuringly, only 12% of drugs in the list have changed, indicating that learning based on 
this resource could have long term relevance for prescribing in practice. 
Some of the changes in the updated list reflect changes in qualification rules, such as 
removal of separate entries for compound preparations and drug groups used in more than 
one therapeutic area. Other changes however are likely to reflect genuine changes in 
prescribing guidelines and practice. For example, in 2010 the European Committee on 
Medicinal Products for Human Use recommended suspension of the marketing 
authorisation of rosiglitazone, a thiazolidinedione, due to emerging evidence of 
cardiovascular risk [13]. Another thiazolidinedione, troglitazone, had previously been 
withdrawn from the British market in 1997 due to hepatotoxicity [14]. Although 
pioglitazone, remains available for prescription and is still included in English guidelines 
produced by the National Institute for Health and Care Excellence (NICE) for the 
management of type 2 diabetes [15], concerns about the safety of this drug class and 
adoption of alternatives, including the dipeptidyl peptidase-4 inhibitors (entering the list in 
2015), likely account for the fall in thiazolidinedione prescribing. Another example is change 
in antiepileptic drug prescribing. Phenytoin, which was included in the 2006-9 list, was put 
on a ‘potential signals of serious risks’ list by the United States Food and Drug 
Administration (FDA) in 2008 and is no longer recommended as either first line or adjunctive 
  
This article is protected by copyright. All rights reserved. 
therapy for the prevention of any seizure type by NICE [16]. Carbamazepine and sodium 
valproate (in both old and new lists), as well as lamotrigine and levetiracetam (entering the 
list in 2015), are preferred. Phenytoin remains on the World Health Organisation List of 
essential medicines [12] and is still listed in NICE guidelines as adjunctive treatment to 
benzodiazepines for status epilepticus. There is therefore a case to include it in the top 100 
list as an emergency drug. As trials seek to replace its use even for status epilepticus with 
safer alternatives [17], we have made the judgement to leave it out of our list. Other 
educators and learners may wish to include it in theirs. Other changes in the list may be due 
to increasing disease prevalence or diagnosis. For example increasing rates of diagnosis of 
dementia and prescription of anti-dementia drugs [18] could be responsible for the entry of 
acetylcholinesterase inhibitors to the list. Differences in data collection between the two 
analyses may also have had an effect. In 2006-9, secondary care prescribing data was 
collected by hand and so only included approximately 7,500 prescriptions, whereas in 2015 
use of electronic prescribing data allowed inclusion of nearly 1.8 million secondary care 
prescriptions. 
Our list was developed using prescribing and dispensing data from England. To determine its 
relevance to an international audience we reviewed it against the WHO essential and 
complementary medicines lists [12]. Over three quarters of drugs on our list are considered 
essential for a basic healthcare system and are therefore likely to be used worldwide. We 
considered the WHO list in its entirety (438 drugs) to be overwhelming for a beginner 
prescriber and feel that our core list has an important place in helping novice prescribers to 
direct most of their initial attention to the most commonly prescribed drugs. 
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A list of drugs to learn about perhaps seems an old fashioned concept in an era where 
healthcare education seeks to be patient-centred, integrated and problem-based and 
curricula are moving to define and assess higher level competencies. Learning to prescribe is 
a complex process, well suited to a spiral curriculum where learners acquire understanding 
of the principles of clinical pharmacology, knowledge of drugs and therapeutics, and skills in 
prescribing in parallel, through multiple ‘visits’ to the topic of increasing complexity [19]. A 
core drug list gives trainee prescribers a tool to focus their acquisition of knowledge around 
drugs that they will use in early clinical practice. It allows them to build their learning from 
knowledge of the pharmacology of individual drugs, through understanding how these 
drugs are used in the management of common diseases to prescribing them in simulated, 
then real, clinical scenarios. The principles and skills developed can then be applied to 
unfamiliar drugs encountered in practice. A core drug list can also help educators to design 
useful learning resources [7] and assessments that are relevant to practice. For example 
learners could be assessed on their knowledge of drugs on the core list, but on their skills in 
information gathering to support safe prescribing of an unfamiliar drug. 
Limitations 
Our analysis has several limitations. The primary care data reflects English prescribing 
practice only, although we consider that it should be broadly representative of UK practice. 
With an appropriate overlay of local clinical–educational judgement, it may have broader 
generalisability. Our finding that over three quarters of drugs on the core list were also on 
the WHO essential medicines list supports this. Secondary care data was obtained from a 
single hospital, and may therefore be affected by local prescribing patterns, population 
characteristics, and specialist services. However, it is reassuring that the large majority of 
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items on the list were prescribed frequently in both primary and secondary care, suggesting 
that most do not reflect specialist or centre-specific practice. Moreover, we applied clinical–
educational judgment to exclude drugs considered to be mainly for specialist use and 
beyond the scope of a new prescriber.  
The method of analysis and definition of drug groupings also had potential to influence the 
results. The complex process of screening BNF sub-paragraphs, classes and individual drugs 
requires some subjective judgement. However, this was informed by considerable 
experience of both clinical practice and prescriber training, aiming to produce educationally 
useful, clinically relevant groups. These are fully described so that educators using the list 
may also apply their own judgment.  
Conclusion 
Personal formularies are valuable tools to improve prescribing skills, but can be difficult to 
develop without help for the trainee prescriber. We have produced a core drug list of the 
most commonly prescribed drug groups in England to assist in this process. We consider 
that it should be generalisable to UK practice and – if supported by appropriate clinical–
educational judgement – more widely. Updating this formulary has resulted in 12 changes 
from 2006-9, keeping the list up to date with contemporary prescribing practice. This core 
drug list is not intended to restrict the scope of teaching or to stifle students’ 
inquisitiveness. Rather, it should be considered as a ‘starter formulary’ to help novice 
prescribers to direct most of their early attention to the most commonly prescribed drugs. 
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Table 1. Drugs, classes and BNF groupings comprising ≥0.1% of both primary and hospital 
prescriptions 
 
Overall 
rank 
Drug, class or BNF 
grouping 
Most commonly prescribed 
example(s) 
Hosp. 
rank 
PCA 
rank 
Hosp. 
% 
PCA 
% 
1 Proton pump inhibitors omeprazole, lansoprazole 3 2 3.0% 5.5% 
2 Statins simvastatin, atorvastatin, pravastatin 9 1 2.3% 6.5% 
3 Paracetamol  1 11 6.2% 2.3% 
4 Beta-blockers bisoprolol, atenolol, propranolol 17 5 1.8% 3.6% 
5 Calcium and vitamin D  11 12 2.1% 2.1% 
6 Calcium-channel blockers amlodipine, felodipine, diltiazem, 
nifedipine, lercanidipine  
21 4 1.8% 3.7% 
7 H1 receptor antagonists cyclizine, cetirizine, loratadine, 
fexofenadine, chlorphenamine 
6 19 2.7% 1.6% 
8 Aspirin  18 8 1.8% 2.8% 
9 Opioids: weak/moderate tramadol, codeine, dihydrocodeine 5 21 2.8% 1.4% 
10 Opioids: strong morphine 2 27 5.2% 1.2% 
11 Beta2 agonists salbutamol, salmeterol 22 10 1.5% 2.3% 
12 Angiotensin-converting 
enzyme inhibitors 
ramipril, lisinopril, perindopril 30 3 1.1% 4.3% 
13 Diuretics, loop furosemide, bumetanide 12 22 2.1% 1.4% 
14 Vitamin K antagonists warfarin 6 28 2.5% 1.1% 
15 Vitamins folic acid, thiamine hydrochloride, 
vitamin B group 
16 20 1.8% 1.5% 
16 Non-steroidal anti-
inflammatory drugs 
naproxen, ibuprofen 28 13 1.1% 2.1% 
17 Penicillins, broad 
spectrum 
amoxicillin, co-amoxiclav 19 24 1.8% 1.4% 
18 Laxatives - osmotic macrogol, lactulose 13 33 2.1% 0.9% 
19 Anti-depressants, selective 
serotonin re-uptake 
inhibitors 
citalopram, sertraline, fluoxetine 42 6 0.7% 3.2% 
20 Corticosteroids, systemic prednisolone 10 38 2.1% 0.8% 
21 Laxatives, stimulant senna, docusate sodium 7 41 2.5% 0.7% 
22 Corticosteroids, inhaled beclometasone, fluticasone, 
budesonide 
39 14 0.8% 2.0% 
23 Thyroid hormones levothyroxine 50 7 0.6% 2.9% 
24 Benzodiazepines diazepam, temazepam, lorazepam 26 32 1.2% 1.0% 
25 Alpha-adrenoceptor 
blocking drugs 
doxazosin, tamsulosin 34 25 0.8% 1.3% 
  
This article is protected by copyright. All rights reserved. 
26 Biguanides metformin 45 15 0.7% 1.9% 
27 Insulin  24 43 1.3% 0.7% 
28 Angiotensin-II receptor 
antagonists 
losartan, candesartan, irbesartan 54 16 0.5% 1.8% 
29 Corticosteroids, topical hydrocortisone 63 9 0.4% 2.4% 
30 Gabapentin and 
pregabalin 
 43 29 0.7% 1.0% 
31 Anti-depressants, tricyclic 
and related drugs 
amitriptyline 56 19 0.4% 1.6% 
32 Anti-platelet drugs clopidogrel 41 34 0.7% 0.9% 
33 Anti-fungal drugs clotrimazole, ketononazole 31 45 1.0% 0.6% 
34 Histamine (H2)-receptor 
antagonists 
ranitidine 25 51 1.3% 0.5% 
35 Diuretics, thiazide and 
thiazide-like 
Bendroflumethiazide, indapamide 65 18 0.3% 1.7% 
36 Emollients  58 31 0.4% 1.0% 
37 Nitrates isosorbide mononitrate, glyceryl 
trinitrate 
48 42 0.6% 0.7% 
38 Trimethoprim  35 55 0.8% 0.4% 
39 Iron ferrous fumarate, ferrous sulfate 51 40 0.6% 0.7% 
40 Bisphosphonates alendronic acid 57 36 0.4% 0.8% 
41 Penicillins, penicillinase-
resistant 
flucloxacillin 46 54 0.6% 0.4% 
42 Sulfonylureas gliclazide 67 35 0.3% 0.8% 
43 Macrolides clarithromycin 53 49 0.5% 0.5% 
44 Gout and hyperuricaemia allopurinol 60 48 0.4% 0.5% 
45 Alginates and antacids  59 50 0.4% 0.5% 
46 Anti-depressant drugs, 
other 
venlafaxine, mirtazapine 80 30 0.2% 1.0% 
47 Z drugs zopiclone 66 46 0.3% 0.6% 
48 Ocular lubricants (artificial 
tears) 
hypromellose 75 39 0.3% 0.8% 
49 Anti-emetics, dopamine 
(D2)-receptor antagonists 
metoclopramide, domperidone 27 88 1.2% 0.2% 
50 Anti-muscarinics, 
cardiovascular and 
gastrointestinal uses 
atropine, hyoscine butylbromide 52 64 0.1% 0.5% 
51 Anti-psychotics: 2nd 
generation 
quetiapine, olanzapine, risperidone 81 37 0.2% 0.8% 
52 Anti-muscarinics, tiotropium, ipratropium bromide 73 47 0.3% 0.6% 
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bronchodilators 
53 Cardiac glycosides digoxin 61 61 0.4% 0.3% 
54 Methotrexate  44 79 0.7% 0.2% 
55 Anti-muscarinics, 
genitourinary uses 
solifenacin, tolterodine, oxybutynin 92 44 0.2% 0.6% 
56 Anti-proliferative 
immunosuppressants 
azathioprine 32 104 1.0% 0.1% 
57 Tetracyclines doxycycline 90 52 0.2% 0.4% 
58 Aldosterone antagonists spironolactone 76 66 0.3% 0.3% 
59 Metronidazole  64 81 0.4% 0.2% 
60 Dipeptidyl peptidase-4 
inhibitors 
sitagliptin, linagliptin 95 57 0.2% 0.4% 
61 Anti-motility drugs loperamide 68 84 0.3% 0.2% 
62 Quinine sulfate  97 56 0.2% 0.4% 
63 Dopaminergic drugs used 
in parkinsonism 
co-careldopa (carbidopa / levodopa)  99 58 0.2% 0.4% 
64 Lamotrigine  101 59 0.2% 0.4% 
65 Direct oral anticoagulants rivaroxaban, apixaban, dabigatran 94 69 0.2% 0.3% 
66 Anti-psychotics: 1st 
generation 
haloperidol  69 94 0.3% 0.1% 
67 Mucolytics carbocisteine 81 78 0.2% 0.2% 
68 Levetiracetam  74 90 0.3% 0.2% 
69 Prostaglandin analogues latanoprost 112 53 0.1% 0.4% 
70 Penicillin benzylpenicillin, 
phenoxymethylpenicillin 
93 75 0.2% 0.2% 
71 Valproate  107 63 0.1% 0.3% 
72 5α-reductase inhibitors finasteride 109 62 0.1% 0.3% 
73 Chloramphenicol   115 65 0.1% 0.3% 
74 Aminosalicylates mesalazine 103 77 0.1% 0.2% 
75 Nitrofurantoin  113 73 0.1% 0.2% 
76 Carbamazepine  117 72 0.1% 0.2% 
77 Antivirals aciclovir 84 105 0.2% 0.1% 
78 Cephalosporins ceftriaxone, cefalexin 85 106 0.2% 0.1% 
79 Local anaesthetics lidocaine 116 92 0.1% 0.1% 
80 Amiodarone  100 108 0.2% 0.1% 
81 Drugs used in substance 
dependence 
nicotine, methadone 111 100 0.1% 0.1% 
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Abbreviations: BNF, British national formulary; PCA, prescription cost analysis; Hosp., 
hospital. 
For each drug the prescribing frequency in terms of rank and percentage of prescriptions 
are shown for both primary (PCA) and secondary (hosp.) care. The average rank in both 
healthcare settings was calculated and determined the overall rank. 
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Table 2. Drugs, classes and BNF groupings comprising ≥0.2% prescriptions in primary care 
but <0.1% prescriptions in secondary care 
 
 Drug, class or BNF grouping Most commonly 
prescribed example(s) 
PCA rank PCA 
(%) 
1 Oestrogens and progestogens combined 
ethinylestradiol, 
desogestrel, estradiol 
27 1.2% 
2 Phosphodiesterase (type 5) 
inhibitors 
sildenafil 61 0.3% 
3 Acetylcholinesterase inhibitors donepezil 72 0.2% 
4 Serotonin (5HT1)-receptor agonists sumatriptan 75 0.2% 
5 Leukotriene receptor antagonists montelukast 79 0.2% 
6 Drugs for breast cancer tamoxifen 83 0.19% 
 
Abbreviations: BNF, British national formulary; PCA, prescription cost analysis 
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Table 3. Drugs, classes and BNF groupings comprising ≥0.3% prescriptions in secondary 
care but <0.1% prescriptions in primary care 
 
 Drug, class or BNF grouping Most commonly 
prescribed example(s) 
Hosp. 
rank 
Hosp % 
1 Heparins enoxaparin, heparin 4 2.9% 
2 Serotonin (5HT3)-receptor 
antagonists 
ondansetron 8 2.4% 
3 Oxygen  21 1.7% 
4 Quinolones ciprofloxacin, 
moxifloxacin 
37 0.8% 
5 Penicillins, anti-pseudomonal piperacillin 
sodium/tazobactam 
sodium 
38 0.8% 
6 Vancomycin  48 0.6% 
7 Aminoglycosides gentamicin 72 0.3% 
 
Abbreviations: BNF, British national formulary; Hosp., hospital. 
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Table 4. Drugs identified from emergency guidelines not qualifying for the core list by 
prescribing frequency but considered to be core learning for new prescribers 
 
1 Activated charcoal 
2 Adrenaline (epinephrine) 
3 Adenosine 
4 Acetylcysteine 
5 Fibrinolytics e.g. alteplase 
6 Naloxone 
 
Drugs from emergency guidelines are in alphabetical order 
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Table 5. Changes in core drug list between 2006-9 and 2015 
 
Drugs dropping out of the core list New entrants to the list 
Anti-emetics, phenothiazines2 Acetylcholinesterase inhibitors 
Compound (beta-2 agonist corticosteroid) 
inhalers1 
Antiproliferative immunosuppressants 
Dipyridamole2 Antivirals 
Electrolytes e.g. potassium, magnesium1 Sex hormone antagonists for breast 
cancer 
Laxatives, bulk forming2 Chloramphenicol  
Nicorandil3 Dipeptidyl peptidase-4 inhibitors 
Opioids, compound preparations1 Lamotrigine 
Phenytoin2 Leukotriene receptor antagonists 
Potassium sparing diuretics with other 
diuretics (e.g. co-amilofruse)2 
Levetiracetam 
Thiazolidinediones2 Direct oral anticoagulants 
Vaccines and antisera1 Serotonin (5HT1)-receptor agonists 
Anti-histamine anti-emetics combined with 
H1 receptor antagonists in the new list
1 
Mucolytics 
 
1. Drugs dropping out of the list due to changes in qualification rules 
2. Drugs dropping out of the list due to reduction in relative prescribing or dispensing 
frequency 
3. Drug with more specialist use making way for drugs for more generalist use 
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4.  
Table 6. Drugs in the English top 100 starter formulary that are not in the World Health 
Organisation’s essential medicines list 
 
1 Alpha-adrenoceptor blocking drugs 
2 Gabapentin and pregabalin 
3 Emollients 
4 Alginates and antacids 
5 Anti-depressant drugs, other (venlafaxine, mirtazapine) 
6 Z drugs 
7 Ocular lubricants (artificial tears) 
8 Anti-muscarinics, genitourinary uses 
9 Dipeptidyl peptidase-4 inhibitors 
10 Direct oral anticoagulants 
11 Mucolytics e.g. carbocisteine 
12 Levetiracetam 
13 5α-reductase inhibitors 
14 Phosphodiesterase (type 5) inhibitors 
15 Acetylcholinesterase inhibitors 
16 Serotonin (5HT1)-receptor agonists 
17 Leukotriene receptor antagonists 
18 Adenosine 
On the complementary list 
19 Anti-proliferative immunosuppressants e.g. azathioprine 
20 Amiodarone 
21 Drugs for breast cancer e.g. tamoxifen 
22 Fibrinolytics e.g. streptokinase 
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Figure 1 Flow diagram showing acquisition, exclusion and processing of prescribing data 
from primary and secondary care and emergency guidelines to produce the core drug list 
